Search this site
NICE DSU
  • Home
  • Training
  • Appraisal specific
  • Methods development
  • TSDs
  • Publications
  • Contact
NICE DSU
  • Home
  • Training
  • Appraisal specific
  • Methods development
  • TSDs
  • Publications
  • Contact
  • More
    • Home
    • Training
    • Appraisal specific
    • Methods development
    • TSDs
    • Publications
    • Contact

Crohn’s disease

Adalimumab and Infliximab

NICE appraisal

TA187 Use of tumour necrosis factor alpha (TNF a) inhibitors (adalimumab, and infliximab [review]) for Crohn’s disease (review of TA40) (May 2010)

DSU reports

DSU response to comments on DSU Crohn’s Report 2 (PDF, 85KB) (August 2009)

Use of tumour necrosis factor alpha (TNF a) inhibitors (adalimumab and infliximab) for Crohn’s Disease – Report 2 (PDF, 372KB) (June 2009)

Use of tumour necrosis factor alpha (TNF a) inhibitors (adalimumab and infliximab) for Crohn’s Disease (PDF, 61KB) (January 2009)

Tel: +44 114 222 0801Email: dsuadmin@sheffield.ac.ukNICE Decision Support Unit
ScHARR
Regent Court
30 Regent Street
Sheffield
S1 4DA 
Accessibility statement
Report abuse
Page details
Page updated
Report abuse